despite reduce cardiovascular cv event erdogan damage current pharmacology strategy disease remain primary caps death world pharmacology therapy base resin angiotensin system ra blocked use extent treatment hypertens heart failure remodel spite success prevail reside risk remain still high novel approach must disco effect acting ai new import target counterbal vasoconstrictiveprolif ang hydroxy slower abl bind ii type receptor review experiment revid suggest active protect vessel possible kidney adverse well 